# Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC

> **NCT04659369** · PHASE1 · TERMINATED · sponsor: **Taizhou Mabtech Pharmaceutical Co.,Ltd** · enrollment: 21 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** CMAB819
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04659369
- **Lead sponsor:** Taizhou Mabtech Pharmaceutical Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-24
- **Primary completion:** 2023-10-16
- **Final completion:** 2023-10-16
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Difficult to recruit subjects
- **Last updated:** 2024-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04659369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04659369, "Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04659369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*